TABLE 1

Pharmacokinetic characteristics and distribution of RIF in pulmonary ELF and BALCs after monotherapy with 10 mg/kg RIF and after coadministration of 7.5 mg/kg CLR in nine healthy foals

Mean ± S.D. values are given.

	AUC_0–12h	Maximal Plasma Concentration	Minimal Plasma Concentration	Time to Maximal Plasma Concentration	t_1/2	Concentration at 12 h
	AUC_0–12h	Maximal Plasma Concentration	Minimal Plasma Concentration	Time to Maximal Plasma Concentration	t_1/2	ELF	BALCs
	μg × h/ml	μg/ml	μg/ml	h	h	μg/ml
RIF
Without CLR	160 ± 48.8	18.1 ± 5.59	10.8 ± 3.66	3.66 ± 2.52	14.7 ± 3.18	8.49 ± 4.10	4.91 ± 1.04^††
With CLR	168 ± 65.0	17.7 ± 6.75	11.0 ± 5.01	3.42 ± 2.58	14.5 ± 5.01	8.12 ± 5.86	6.65 ± 3.66^†
DAc-RIF
Without CLR	0.91 ± 0.42	0.10 ± 0.05	0.08 ± 0.05	3.86 ± 2.87	12.1 ± 4.05	0.19 ± 0.10^††	1.44 ± 0.62^††
With CLR	0.75 ± 0.22	0.08 ± 0.02	0.07 ± 0.02	5.34 ± 3.48	10.1 ± 1.85	0.18 ± 0.07^††	1.73 ± 1.42^††

↵† p < 0.05,
↵†† p < 0.01, versus plasma concentration at 12 h (Mann-Whitney test).